

## AlphaFold2 transmembrane protein structure prediction shines

Tamás Hegedűs<sup>1,2,\*</sup>, Markus Geisler<sup>3</sup>, Gergely Lukács<sup>4</sup>, Bianka Farkas<sup>1,5</sup>

<sup>1</sup> Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, HU

<sup>2</sup> TKI, Eötvös Loránd Research Network, Budapest, HU

<sup>3</sup> Department of Biology, University of Fribourg, Fribourg, Switzerland

<sup>4</sup>Department of Physiology and Biochemistry, McGill University, Montréal, Quebec, Canada

<sup>5</sup> Faculty of Information Technology and Bionics, Pázmány Péter Catholic University, Budapest, HU

Tamas Hegedus

23 **Abstract**

24 Transmembrane (TM) proteins are major drug targets, indicated by the high percentage of prescription  
25 drugs acting on them. For a rational drug design and an understanding of mutational effects on protein  
26 function, structural data at atomic resolution are required. However, hydrophobic TM proteins often resist  
27 experimental structure determination and in spite of the increasing number of cryo-EM structures, the  
28 available TM folds are still limited in the Protein Data Bank. Recently, the DeepMind's AlphaFold2  
29 machine learning method greatly expanded the structural coverage of sequences, with high accuracy.  
30 Since the employed algorithm did not take specific properties of TM proteins into account, the validity  
31 of the generated TM structures should be assessed. Therefore, we investigated the quality of structures  
32 at genome scales, at the level of ABC protein superfamily folds, and also in specific individual cases. We  
33 tested template-free structure prediction also with a new TM fold, dimer modeling, and stability in  
34 molecular dynamics simulations. Our results strongly suggest that AlphaFold2 performs astoundingly  
35 well in the case of TM proteins and that its neural network is not overfitted. We conclude that a careful  
36 application of its structural models will advance TM protein associated studies at an unexpected level.

37 **Introduction**

38

39 Although enormous resources were devoted to predict proteins' structure for many decades, predicting a  
40 protein structure from its sequence remained a challenging task<sup>1</sup>. There was a change in the last Critical  
41 Assessment of Protein Structure Prediction (CASP) competition<sup>2</sup> when two neural network based  
42 approaches, RoseTTAFold<sup>3</sup> and AlphaFold2<sup>4</sup> (AF2), were excelled. Importantly, DeepMind generated  
43 AF2-predicted structures for the human<sup>5</sup> and 20 other proteomes and they were deposited to EBI  
44 (<https://alphafold.ebi.ac.uk>). Moreover, to ease the running of predictions for researchers, DeepMind<sup>6</sup>  
45 and community Google Collaboration notebooks<sup>7</sup> have been generated, albeit applying some  
46 simplifications. AlphaFold2 was trained using multiple sequence alignments (MSA) and experimental  
47 protein structures deposited before April 2018. Five different models were trained (e.g. with different  
48 random seeds, with or without structural templates) to promote an increased diversity in structure  
49 predictions<sup>6</sup>. The input for prediction is the sequence of a single protein chain, used for MSA generation  
50 and structural template search. The quality of the resulted structural models is characterized by the mean  
51 of per residue pLDDT (predicted Local Distance Difference Test) score (which takes values between 0  
52 and 100, the higher value is better) and the structures are ranked accordingly<sup>4</sup>. The pLDDT confidence  
53 measure predicts the accuracy of the C $\alpha$  Local Distance Difference Test (LDDT-C $\alpha$ ) for the corresponding  
54 prediction. Although this means that the high accuracy and reliability of AF2 observed in CASP14 can  
55 be transferred to predicting the structure of any protein sequences (or whole proteomes)<sup>4,5</sup>, this has not  
56 been validated yet and scientists do not have a clear indication how well AF2-predicted structures can be  
57 trusted. Even more, there is a special skepticism in the field of transmembrane proteins, which are  
58 challenging to investigate using either experimental or computational methods, especially because  
59 AlphaFold2 was not tuned for TM proteins. It is also not known, whether the structural model with the  
60 highest pLDDT score always corresponds to the native structure. In order to tackle these issues, we  
61 investigated whether AF2-predicted human  $\alpha$ -helical TM protein structures exhibit correctly located TM

62 regions. To demonstrate at a higher resolution that the predicted TM folds are native, we compared  
63 predicted structures of the ATP Binding Cassette (ABC) superfamily from the AF2-predicted 21  
64 proteomes to existing experimental ABC folds. ABC proteins play a role in important cellular processes  
65 in all types of organisms and most of them transport substrates through the cell membrane in an ATP  
66 dependent manner<sup>8-10</sup>. ABCC7/CFTR is a special member, which is an ATP-gated chloride channel and  
67 includes a long intrinsically disordered regulatory R domain<sup>11,12</sup>. The functional form of ABC proteins is  
68 built from two highly conservative nucleotide binding domains (NBDs) and two transmembrane domains  
69 (TMDs) which can be encoded in one or separate peptide chains. The low conservation of their TMDs  
70 are related to diverse functions and their currently known TM folds are also structurally divergent and  
71 can be classified into eight groups (Pgp-, ABCG2-, MalFG-, BtuC-, EcFT-, LptFG-, MacB-, and MlaE-  
72 like folds)<sup>13,14</sup>. Our results demonstrate that AlphaFold2 provides reliable protein structures also for  
73 transmembrane proteins and can solve many issues associated with transmembrane protein structures.

74

75 **Results**

76

77 **TM helices membrane topology assignments in AlphaFold2 structures**

78 First, we split the human AF2 structures to soluble and transmembrane sets using the HTP (Human  
79 Transmembrane Proteome) database<sup>15</sup>, calculated the mean pLDDT score for each protein, and plotted  
80 their distribution (Fig. 1A and Fig. S1). Mean pLDDT values were also calculated separately for the TM  
81 and non-TM regions of transmembrane proteins. Intriguingly, soluble proteins exhibited a broader  
82 distribution and a significant area at lower pLDDT values compared to TM proteins. This was  
83 unexpected, since the majority of the AlphaFold2 learning set inherently included more soluble protein  
84 templates and the algorithm was not tuned for transmembrane proteins. However, correlation between  
85 low pLDDT values and disordered segments was observed<sup>5</sup>, thus our observation strongly suggested that  
86 more soluble proteins possess disordered regions than TM proteins. Interestingly, a very large portion of

87 TM regions (53%) were predicted with high pLDDT scores (>90) (Fig. 1A) suggesting that AF2 captured  
88 the rules governing protein structures within the hydrophobic region.

89 Next, we compared the spatial localization of TM helices in AF structures corresponds with rational  
90 and physiological helix orientation in a lipid bilayer slab by using the Constrained Consensus Topology  
91 prediction (CCTOP) software<sup>16</sup>, which includes information from both experimental and computational  
92 sources. We separated the start and end positions of predicted TM helices to two residue sets according  
93 to their localization relative to the opposite sides of the bilayer. The distance between the center of  
94 geometry of the two sets were calculated and its distribution is plotted (Fig. 1B). The majority of the  
95 membrane thickness values were in the range between 20 and 30 Å that is in the range of the hydrophobic  
96 region thickness. In order to support this finding with experimental data, the hydrophobic thickness of  
97 experimentally determined human transmembrane protein structures was retrieved from the PDBTM  
98 database<sup>17</sup>. The AF2 and experimental distribution largely overlapped (Fig. 1B). These observations  
99 suggested that hydrophobic thickness values below 15 Å and above 35 Å may indicate an erroneous AF2  
100 structure (12%, 725 out of 5952, Table S1). We also investigated the distribution of pLDDT scores versus  
101 hydrophobic thickness (Fig. 1C). This plot indicated that AF2 structures with non-physiological thickness  
102 values can process very high pLDDT scores, consequently, these scores alone may be insufficient to  
103 select correct TM structures in blind predictions.

104 An inaccurate TM topology prediction of CCTOP may provide an outlier hydrophobic thickness in  
105 the case of a correct AF2-predicted structure. The CCTOP reliability versus thickness plot (Fig. 1D)  
106 indicated that the topology of most proteins, whose AF2-predicted structure exhibited hydrophobic  
107 thickness within the 15-30 Å regime, was predicted with high reliability. Structures with lower  
108 hydrophobic thickness values and high CCTOP reliability were likely inaccurately predicted by  
109 AlphaFold2, while structure predictions with lower thickness and lower CCTOP scores were located in  
110 the twilight zone. Intriguingly, we observed that some of these entries may have low topology reliability  
111 because of their existence in complexes, but AF2 predicted the monomeric form correctly (Fig. S2). This

112 suggests that AF2 may also be used to identify and aid the correction of improper membrane topology  
113 predictions.

114

115 **The experimental TM helix packing of ABC transporters overlaps with AF2-predictions**

116 Structures of ABC superfamily members are an excellent choice to investigate AlphaFold2 performance  
117 on TM proteins, since the currently available 51 PDB entries including ABC transmembrane domains  
118 are diverse and can be classified into eight different folds represented by PDB structures (Fig. S3)<sup>13,14</sup>.  
119 For assessing AF2 TM protein predictions at a higher resolution, we aimed to compare AF2-built ABC  
120 TM folds with experimentally determined folds.

121 In order to select ABC structures from the 21 proteomes with AF2 predictions, a stringent PFAM  
122 search was performed with 29 PFAM Hidden Markov Models (Table S2) that resulted in 1,126 hits. For  
123 assessing the similarity of structures to the eight selected reference folds (Fig. S3), we employed  
124 Template Modeling score (TM-score)<sup>18,19</sup>. TM-scores below 0.5 indicate unrelated structures, while and  
125 above 0.5 roughly the same fold<sup>19</sup>. We calculated TM-scores between the 1,126 AF2-predicted  
126 transmembrane ABC structures and the eight reference structures. The best out of eight scores were saved  
127 for each structure. We found that 99.5% of the TM-score values were above 0.5 (Fig. 2A). Five out of  
128 the remaining six structures with lower TM-scores (O69723, P33359, Q2FVH1, Q2FVE9, Q2FVG9)  
129 included MalFG-like folds, but the scores were low because of their variable number of TM helices and  
130 possible disordered regions. One protein (Q2G2E2, Fig. 2B), which matched the YitT\_transmembrane  
131 PFAM entry, was somewhat similar to the aquaporin/GlpF fold (e.g. PDBID: 1FX8) and suggested that  
132 the YitT\_transporter PFAM entry is wrongly classified. Indeed, this fold belongs to the non-ABC,  
133 Novobiocin Exporter (NbcE) Family in the Transport Classification Database<sup>20</sup>. In addition to  
134 discovering potentially new folds, AlphaFold2 can aid predicting the structural class of PFAM families,  
135 such as five families out of the ABC transmembrane HMMs (Table S2).

136 Some of the predicted ABC structures included two additional N-terminal TM-like helices, which  
137 were somewhat distant from the core TM domain and likely are membrane associated regions, such as  
138 the L0/Lasso motif of ABCC proteins<sup>21-23</sup>. In many cases, membrane interacting regions, loops, and  
139 mobile regions not resolved in experimental structures have been rationally modeled by AF2, based on  
140 visual inspection (see below and Fig. S2). Thus the AF2 machine learning method clearly grasped some  
141 knowledge on a lipid bilayer around TM proteins.

142

#### 143 **AF2 provides dimers, MD-stable structures, and hints for flaws in experimental structures**

144 Since AlphaFold2 also used templates for structural modeling and some of the resulted structures may  
145 be considered as advanced homology models, we also performed AF2 modeling of highly studied human  
146 ABC proteins with disabled template usage.

147 Our targets included half transporter ABCG proteins, which consist of an NBD and a TMD in a  
148 polypeptide chain and function in homodimeric or heterodimeric complexes<sup>14</sup>. The first experimentally  
149 determined ABCG2-like fold was the X-ray structure of the ABCG5/ABCG8 heterodimer (PDBID:  
150 5DO7) published in 2016<sup>24</sup>. Our first observation with the AF generated ABCG8 structure was regarding  
151 its soluble NBD. After the publication of the first ABCG2 structure<sup>25</sup>, structural alignment and sequence  
152 analysis indicated a registry shift in the first  $\beta$ -strand of ABCG8 NBD (Fig. 3A) that happened because  
153 of the low resolution of this region. Although AlphaFold2 exploited the 5DO7 structure as a template,  
154 the AF2-predicted ABCG8 structure did not have this error (Fig. 3A). An ABCG5/ABCG8 structure with  
155 a correct registry was also released on 07/04/2021 (PDBID: 7JR7<sup>26</sup>), but AF2 template search<sup>5</sup> used  
156 PDB70 downloaded on 10/02/2021.

157 To assess ABCG5/ABCG8 TMD predictions, we ran AF2 without any application of templates.  
158 First, the ABCG5 TMD predictions were of exceptionally good quality regarding the RMSD (root mean  
159 square deviation) and TM-score values of 0.78 $\text{\AA}$  and 0.94, respectively, when compared to the ABCG5  
160 chain in the 5DO7 structure. Second, we investigated ABCG5/ABCG8 heterodimer predictions. Since

161 only single chains can be submitted to AlphaFold2, we concatenated the two sequences with a part of the  
162 CFTR R domain sequence (a.a. 675-800). This disordered sequence was sufficiently long not to constrain  
163 the conformational space of the dimer and did not exhibit strong intramolecular interactions even in its  
164 native, AF2-predicted structural environment (Fig. S4). The predicted TMD dimer exhibited 0.001Å  
165 RMSD and 1.00 TM-score value when compared with the 5DO7 structure (Fig. 3B).

166 To investigate if AlphaFold2 can distinguish between intra- and intermolecular interactions in the  
167 case of homomeric complexes, we performed a prediction with ABCG2, which forms homodimers<sup>27</sup>.  
168 The complex of the two identical TMDs was also predicted exceptionally well (2.42Å RMSD and 0.9  
169 TM-score when compared to PDBID: 6VXF). Interestingly, cysteine residues forming intra- and  
170 intermolecular disulfide bonds were close to each other (Fig. S5).

171 We also examined how AF2 structural models can supplement or replace homology models in  
172 molecular dynamics (MD) simulations. The TM regions of distant ABC proteins exhibit low sequence  
173 conservation with good accordance of their dissimilar functions and substrates. However, their folds in a  
174 family are highly conserved, thus homology modeling can provide high quality homology models<sup>28-31</sup>.  
175 We chose AtABCG36/PEN3/PDR8<sup>32</sup> from the model plant *Arabidopsis thaliana*, which is a well-  
176 investigated full transporter of the ABCG subclass for that no structures yet exist. When the homology  
177 model exhibiting two ABCG2-like TMDs (Fig. 3C) was inserted into a membrane bilayer and subjected  
178 to MD, one portion of an  $\alpha$ -helix, which is part of the central drug binding pocket, exhibited fast unfolding  
179 in an equilibrium MD simulation. Then the AF2-predicted AtABCG36 structure under the same  
180 conditions remained stable in an MD simulation (Fig. S6).

181 The CFTR/ABCC7 chloride channel is also a member of the ABC superfamily with a Pgp-like fold.  
182 The functional mechanism of this protein is of interest, since some mutations effect channel gating and  
183 cause cystic fibrosis<sup>33</sup>. One of its structures was determined using cryo-EM under activating condition,  
184 in the presence of ATP and phosphorylation, but the extracellular pore of the channel remained in a closed  
185 state, most likely due to a kink in TM8, corresponding to an unwound segment in the transmembrane

186 region<sup>34</sup> (Fig. 3F). This kink is present in most CFTR structures (PDBIDs: 5UAK, 6O2P, 6MSM, 6O1V,  
187 5UAR, 5W81)<sup>34-37</sup>. However, the kink is absent from the chicken CFTR structure (PDBIDs: 6D3S and  
188 6D3R)<sup>38</sup> and such a conformation has not been detected in other ABC structures. We performed  
189 equilibrium simulations with the 5W81 structure<sup>12</sup> to detect channel opening, but appearance of tunnels  
190 with sufficient diameter to pass chloride ions were rare events and was observed only once out of 22  
191 simulations (6x100ns + 16x35ns, 427/116,000 frames, 0.004%). Intriguingly, many of the conformations  
192 provided a tunnel opened towards lipid molecules of the extracellular membrane leaflet (Fig. 3G). After  
193 correcting the kink by homology modelling based on the MRP1 structure (PDBID: 5UJ9) (Fig. 3F),  
194 opening of the extracellular pore could be observed in 5 out of 6 simulations at a higher probability  
195 (6x100ns, 2,245/60,000 frames, 3.74%). Remarkably, modeling CFTR TMDs using AlphaFold2 without  
196 CFTR or any templates resulted in a conformation similar to that of MRP1 with a straight TM8 helix  
197 (Fig. 3F,H). Since TM8 has been suggested to be flexible regarding to its membrane embedment<sup>39</sup>, it is  
198 likely sensitive to its environment and based on the functional assays and the structure determination  
199 protocol<sup>35</sup>, the detergent added in the last step (3 mM fluorinated Fos-Choline-8) likely biased the  
200 structure.

201

## 202 **Prediction of a new TM fold, never seen by AlphaFold2**

203 The most obvious test for assessing AlphaFold2's ability to predict membrane protein structures, was  
204 running a blind prediction. For this objective we used the multiple peptide resistance factor (MprF)  
205 transmembrane domain sequence, whose structures was published this year by Song *et al.*<sup>40</sup> (PDBIDs:  
206 6LVF and 7DUW) Thus their novel TM fold (Fig. 4A) was not present in the AlphaFold2's training set.  
207 We disabled template usage in AlphaFold2 run, since the 6LVF structure is already in the pdb70 dataset  
208 used by AF2. Since the top ranked AF2 structure was not a matching AF2-prediction (Fig. 4B), we  
209 performed the prediction several times (n=6) and compared the predicted structures to the transmembrane  
210 domain of 7DUW using TM-score. Plotting the pLDDT scores versus TM-scores (Fig. 4C) indicated that

211 among the 25 predicted structures the one with the best pLDDT score was the most similar to the target  
212 structure (highest TM-score in the set) (Fig. 4D). In addition, this plot also included two important hints  
213 regarding evaluating predicted structures. First, AF2 structures with high pLDDT values can be highly  
214 distinct from the native fold. Second, AF2 neural network model 5 did not perform well on this membrane  
215 protein, while model 2 and model 4 even in the middle pLDDT range provided the same fold as the  
216 native. We were unsuccessful in predicting the dimeric form of MprF that was likely due to the very  
217 small protein-protein interaction interface and the fact that lipid molecules are also play a role in dimer  
218 stabilization<sup>40</sup>.

219

## 220 Discussion

221

222 We demonstrated that at least ~90% of the AF2-predicted TM structures of the human proteome  
223 represented membrane-protein like structures, using the most available and reliable measure, the location  
224 of TM helices from consensus predictions and experimental structures, for assessing TM protein structure  
225 quality at a large scale. While the pLDDT score distribution did not shift much to lower values compared  
226 to soluble proteins (Fig. S1) it is likely valid to state that AF2 predict TM proteins as good as soluble  
227 proteins. However, predicted TM structures with low hydrophobic thickness and high pLDDT score (Fig.  
228 1C) and our predictions with the novel MprF fold (Fig. 4C) suggest that evaluation depending solely on  
229 pLDDT score may not be sufficient to select the best AF2-predicted model, at least in the case of TM  
230 proteins. A similar conclusion was drawn comparing the AF2-predicted and cryo-EM structures of a  
231 pump-like channelrhodopsin with structural features never seen before<sup>41</sup>. Based on our results, the quality  
232 of AF2 models can also be investigated by MD simulations in low-throughput studies, since low-quality  
233 AF2 models should be as instable as incorrect homology models (Fig. S6) or experimental structures<sup>42</sup>.

234 Our results demonstrate that AlphaFold2 is a highly valuable tool in many areas of TM protein  
235 research. It can highlight proteins with potentially new folds (Fig. 2B) and select them for experimental

236 structure determination, resulting an increase in the experimental fold space. AlphaFold2 can also  
237 associate PFAM families with structural folds that will aid functional annotation of yet uncharacterized  
238 proteins (Table S2). Importantly, the AF2-predicted AtABCG36 structure revealed that AF2 in  
239 combination with a structure alignment method (e.g. TMalign) can support any methods using sequence  
240 alignments. The stability of TM2 of AF2 AtABCG36 model in MD simulations strongly suggests that  
241 the AlphaFold2s model building and relaxation protocols provide valid inputs also for drug/protein  
242 interactions studies.

243 AlphaFold2 is being suggested to be exploited in molecular replacement protocol aiding  
244 experimental structure determination<sup>43</sup>. One of our results, that the register shift in ABCG8 NBD is  
245 corrected by AF2 (Fig. 3A), supports this type of applications, and also suggests that comparison of PDB  
246 structures with the corresponding AF2 structures may detect structural errors and contribute to  
247 improvement of PDB quality. This observation of corrected registry shift in the presence of an incorrect  
248 template and the absence of the kink in CFTR TM8 upon disabling template usage, are strong indications  
249 that the neural network behind AlphaFold2 is not overfitted and it can overcome memory footprints  
250 originating from training.

251 We also demonstrated that AF was capable to predict transmembrane dimer structures independently  
252 of their homo- or heteromeric nature (Fig. 3B and Fig. S5). Though, this success may be at least partially  
253 resulted by the footprint of these complexes themselves in the AF2 neural network. Interestingly, AF2  
254 was not trained for multimer predictions and it was also reported being successful for protein-peptide  
255 docking<sup>44</sup>, in which peptides were not involved in alignments. These observations suggest that AF2  
256 “learned something more” than protein structure and something deeper on the mechanism of protein  
257 folding. Since knowledge on the folding steps and intermediate structures is important to understand and  
258 cure folding diseases<sup>45,46</sup>, deciphering hidden information on folding directly or indirectly from AF2  
259 neural network is an important future objective.

260 In summary, our study underscores that AlphaFold2 provides reliable protein structures also for  
261 transmembrane proteins and we demonstrated its unexpected performance in many areas associated with  
262 transmembrane protein structures. The artificial intelligence inside AlphaFold2 can predict various  
263 structural information and correct structure related flaws (e.g. registry shift, alignments, TM topology  
264 prediction, etc.) same as or better than humans.

265

266 **Methods**

267

268 **Databases and associated software.** AlphaFold2 structures predicted for 21 proteomes were  
269 downloaded from <https://alphafold.ebi.ac.uk> in July, 2021. Proteins and their structures are identified in  
270 the manuscript with their UniProt accession number. Human Transmembrane Protein database<sup>15</sup>  
271 (02.06.2021) was received as an XML file from <http://htp.enzim.hu>. The data also contained CCTOP<sup>16</sup>  
272 (<http://cctop.enzim.ttk.mta.hu>) predictions and their reliability values. The hydrophobic thickness of  
273 experimentally determined human TM protein structures was retrieved from the PDBTM database  
274 (<http://pdtm.enzim.hu>, 2021-07-23)<sup>17</sup>. Python was used to parse their XML files.

275 ABC PFAM entries were identified at <https://pfam.xfam.org> (n=29) and extracted from the Pfam-  
276 A.hmm file. The selected entries and their accession numbers are listed in Table S2. The sequence of  
277 every AF2 structure was searched using HMMER hmmsearch (<http://hmmer.org>)<sup>47</sup>. The E parameter was  
278 set to 0.001 and the match length was restricted to a minimum of 90% of the HMM profile length. The  
279 hmmsearch output was parsed using BioPython<sup>48</sup>.

280

281 **Data analysis and visualization.** MDAnalysis<sup>49</sup> and NumPy<sup>50</sup> Python packages were used for  
282 calculation of mean pLDDT values and hydrophobic membrane thickness. The pLDDT value of each  
283 residue were extracted from the B-factor column of AF2 structure files. For TM thickness calculation

284 end positions of TM helices were retrieved from HTP/CCTOP and divided into two groups representing  
285 the two sides of the membrane. Plotting was done with Matplotlib (<https://matplotlib.org>)<sup>51</sup>.

286 TM-score was calculated with TMalign<sup>52</sup>. Reference ABC structures are listed and shown in Fig. S3.  
287 Their TM domains were selected manually.

288 Molecular visualization and RMSD calculation were performed using PyMOL (The PyMOL  
289 Molecular Graphics System, Version 2.4.0 Schrödinger, LLC). RMSD of MD trajectories was calculated  
290 with the GROMACS rms tool.

291

292 **Running AlphaFold2.** AlphaFold2 was downloaded from github and installed as described  
293 (<https://github.com/deepmind/alphafold>) on a Debian 10 box with an AMD Ryzen Threadripper 2950X  
294 16-Core Processor. 96GB RAM was installed and ~75GB peak usage was observed during jackhmmer  
295 run. The calculation was accelerated by an NVidia Quadro P6000 GPU with 24GB RAM, which was  
296 almost fully utilized when the predicted sequence length was 1,571. The required databases were located  
297 on two 2TB HDD in a RAID0 setup. Typical run timings were: “features”: 25-60 min,  
298 “predict\_and\_compile\_model\_\*”: 3-50 min, “relax\_model\_\*”: 1 min - 6 h based on input sequences  
299 between 290 and 1,571 a.a. length.

300 In order to exclude CFTR structures as templates from predictions, we modified run\_alphafold.py,  
301 docker/run\_docker.py, and alphafold/data/templates.py scripts to implement a -skip function. The  
302 modified scripts can be downloaded from <http://alphafold.hegelab.org>. Template usage was disabled by  
303 setting --max\_template\_date option to 1900-01-01. Dimer predictions were run by concatenating  
304 sequences with a part of the intrinsically disordered CFTR R domain, a.a. 675-800. pLDDT scores and  
305 ranking of predicted structures were extracted from the ranking\_debug.json file.

306

307 **Homology modelling.** AtABCG36 (UniProt ACC: Q9XIE2) was homology modeled based on an  
308 ABCG2 homodimer structure (PDBID: 6HZM) using Modeller<sup>53</sup>. Sequence alignment was generated

309 using ClustalW<sup>54</sup> and adjusted manually. One hundred structures were generated and the one with the  
310 best DOPE score was selected for MD simulations.

311 zfCFTR TM7 and TM8 was homology modeled similarly. The two helices were set for modelling  
312 based on the corresponding regions of MRP1 (PDBID: 5UJ9<sup>23</sup>) and the rest was kept static and based on  
313 the 5W81 zfCFTR structure.

314

315 **Molecular dynamics simulations.** MD simulations with AtABCG36 were performed using GROMACS  
316 2019 with the CHARMM36m force field<sup>55,56</sup>. Simulation systems were prepared using CHARMM-  
317 GUI<sup>57,58</sup>. Structural models were oriented according to the OPM (Orientations of Proteins in Membranes)  
318 database<sup>59</sup> and all N- and C-termini were patched with ACE (acetyl) and CT3 (N-Methylamide) groups,  
319 respectively. The proteins were inserted in a bilayer with 1:1 POPC:PLPC (1-palmitoyl-2-oleoyl-sn-  
320 glycero-3-phosphocholine: 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine) in the extracellular  
321 leaflet and 45:40:10:5 POPC:PLPC:POPS:PIP2 (POPS: 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-  
322 serine, PIP2: phosphatidylinositol 4,5-bisphosphate) in the intracellular leaflet. Both systems with the  
323 homology model or the AF2 structure were energy minimized using the steepest descent integrator  
324 (values for max. steps 50,000 and max. force 500 kJ/mol/nm were set). Six equilibration steps, according  
325 to the standard CHARMM-GUI protocol, were applied with decreasing position restraints. In the  
326 production run, Nosé-Hoover thermostat and Parrinello-Rahman barostat with semiisotropic coupling  
327 were employed. Time constants for the thermostat and the barostat were set to 1 picosecond and  
328 5 picosecond, respectively. The fast smooth PME algorithm<sup>60</sup> and LINCS algorithm<sup>61</sup> were used to  
329 calculate electrostatic interactions and to constrain bonds, respectively. GROMACS rmsf tools were used  
330 to calculate RMSF (root mean square fluctuation).

331 Simulations with the zfCFTR structure containing the kinked TM8 have been published and the  
332 protocol and parameters were described there<sup>12</sup>. The structure with the straightened, MRP1-based TM8

333 was subjected to MD simulations using the same protocol, including the same version of GROMACS,  
334 force field, and lipid composition. Channel pathways were determined using CAVER<sup>62</sup> as described<sup>12</sup>.  
335

336 **Data Availability.** All input data are available from public resources and their accession numbers are  
337 listed.  
338

339 **Code availability.** Modified AlphaFold2 scripts can be downloaded from <http://alphafold.hegelab.org>.  
340

## 341 References

342

- 343 1. Kuhlman, B. & Bradley, P. Advances in protein structure prediction and design. *Nat. Rev. Mol. Cell Biol.* **20**, 681–697 (2019).
- 344 2. Pereira, J. *et al.* High-accuracy protein structure prediction in CASP14. *Proteins* (2021) doi:10.1002/prot.26171.
- 345 3. Baek, M. *et al.* Accurate prediction of protein structures and interactions using a three-track neural network. *Science* **373**, 871–876 (2021).
- 346 4. Jumper, J. *et al.* Highly accurate protein structure prediction with AlphaFold. *Nature* 1–11 (2021) doi:10.1038/s41586-021-03819-2.
- 347 5. Tunyasuvunakool, K. *et al.* Highly accurate protein structure prediction for the human proteome. *Nature* 1–9 (2021) doi:10.1038/s41586-021-03828-1.
- 348 6. <https://github.com/deepmind/alphafold>. (DeepMind, 2021).
- 349 7. Mirdita, M., Ovchinnikov, S. & Steinegger, M. *ColabFold - Making protein folding accessible to all*. 2021.08.15.456425 <https://www.biorxiv.org/content/10.1101/2021.08.15.456425v1> (2021) doi:10.1101/2021.08.15.456425.
- 350 8. Hamdoun, A., Hellmich, U. A., Szakacs, G. & Kuchler, K. The incredible diversity of structures and functions of ABC transporters. *FEBS Lett.* **595**, 671–674 (2021).
- 351 9. Sarkadi, B., Homolya, L. & Hegedűs, T. The ABCG2/BCRP transporter and its variants - from structure to pathology. *FEBS Lett.* (2020) doi:10.1002/1873-3468.13947.
- 352 10. Nagy, T. *et al.* The transport pathway in the ABCG2 protein and its regulation revealed by molecular dynamics simulations. *Cell. Mol. Life Sci. CMLS* (2020) doi:10.1007/s00018-020-03651-3.
- 353 11. Csanády, L., Vergani, P. & Gadsby, D. C. STRUCTURE, GATING, AND REGULATION OF THE CFTR ANION CHANNEL. *Physiol. Rev.* **99**, 707–738 (2019).
- 354 12. Farkas, B. *et al.* Discovering the chloride pathway in the CFTR channel. *Cell. Mol. Life Sci. CMLS* (2019) doi:10.1007/s00018-019-03211-4.
- 355 13. Srikant, S. Evolutionary history of ATP-binding cassette proteins. *FEBS Lett.* **594**, 3882–3897 (2020).
- 356 14. Thomas, C. *et al.* Structural and functional diversity calls for a new classification of ABC transporters. *FEBS Lett.* **594**, 3767–3775 (2020).
- 357 15. Dobson, L., Reményi, I. & Tusnády, G. E. The human transmembrane proteome. *Biol. Direct* **10**, (2015).

373 16. Dobson, L., Reményi, I. & Tusnády, G. E. CCTOP: a Consensus Constrained TOPology  
374 prediction web server. *Nucleic Acids Res.* **43**, W408-412 (2015).

375 17. Kozma, D., Simon, I. & Tusnády, G. E. PDBTM: Protein Data Bank of transmembrane proteins  
376 after 8 years. *Nucleic Acids Res.* **41**, D524-529 (2013).

377 18. Zhang, Y. & Skolnick, J. Scoring function for automated assessment of protein structure  
378 template quality. *Proteins* **57**, 702–710 (2004).

379 19. Xu, J. & Zhang, Y. How significant is a protein structure similarity with TM-score = 0.5?  
380 *Bioinforma. Oxf. Engl.* **26**, 889–895 (2010).

381 20. Saier, M. H. *et al.* The Transporter Classification Database (TCDB): 2021 update. *Nucleic Acids  
382 Res.* **49**, D461–D467 (2021).

383 21. Bakos, E. *et al.* Characterization of the amino-terminal regions in the human multidrug  
384 resistance protein (MRP1). *J. Cell Sci.* **113 Pt 24**, 4451–4461 (2000).

385 22. Zhang, Z. & Chen, J. Atomic Structure of the Cystic Fibrosis Transmembrane Conductance  
386 Regulator. *Cell* **167**, 1586-1597.e9 (2016).

387 23. Johnson, Z. L. & Chen, J. Structural Basis of Substrate Recognition by the Multidrug  
388 Resistance Protein MRP1. *Cell* **168**, 1075-1085.e9 (2017).

389 24. Lee, J.-Y. *et al.* Crystal structure of the human sterol transporter ABCG5/ABCG8. *Nature* **533**,  
390 561–564 (2016).

391 25. Taylor, N. M. I. *et al.* Structure of the human multidrug transporter ABCG2. *Nature* **546**, 504–  
392 509 (2017).

393 26. Zhang, H. *et al.* Cryo-EM structure of ABCG5/G8 in complex with modulating antibodies.  
394 *Commun. Biol.* **4**, 526 (2021).

395 27. Henriksen, U., Fog, J. U., Litman, T. & Gether, U. Identification of intra- and intermolecular  
396 disulfide bridges in the multidrug resistance transporter ABCG2. *J. Biol. Chem.* **280**, 36926–36934  
397 (2005).

398 28. Serohijos, A. W. R., Hegedus, T., Riordan, J. R. & Dokholyan, N. V. Diminished Self-  
399 Chaperoning Activity of the ΔF508 Mutant of CFTR Results in Protein Misfolding. *PLoS Comput Biol*  
400 **4**, e1000008 (2008).

401 29. László, L., Sarkadi, B. & Hegedüs, T. Jump into a New Fold-A Homology Based Model for the  
402 ABCG2/BCRP Multidrug Transporter. *PloS One* **11**, e0164426 (2016).

403 30. Khunweeraphong, N., Stockner, T. & Kuchler, K. The structure of the human ABC transporter  
404 ABCG2 reveals a novel mechanism for drug extrusion. *Sci. Rep.* **7**, 13767 (2017).

405 31. Ferreira, R. J., Bonito, C. A., Cordeiro, M. N. D. S., Ferreira, M.-J. U. & Dos Santos, D. J. V. A.  
406 Structure-function relationships in ABCG2: insights from molecular dynamics simulations and  
407 molecular docking studies. *Sci. Rep.* **7**, 15534 (2017).

408 32. Aryal, B. *et al.* ABCG36/PEN3/PDR8 Is an Exporter of the Auxin Precursor, Indole-3-Butyric  
409 Acid, and Involved in Auxin-Controlled Development. *Front. Plant Sci.* **10**, 899 (2019).

410 33. Veit, G. *et al.* From CFTR biology toward combinatorial pharmacotherapy: expanded  
411 classification of cystic fibrosis mutations. *Mol Biol Cell* **27**, 424–433 (2016).

412 34. Zhang, Z., Liu, F. & Chen, J. Conformational Changes of CFTR upon Phosphorylation and ATP  
413 Binding. *Cell* **170**, 483-491.e8 (2017).

414 35. Liu, F., Zhang, Z., Csanády, L., Gadsby, D. C. & Chen, J. Molecular Structure of the Human  
415 CFTR Ion Channel. *Cell* **169**, 85-95.e8 (2017).

416 36. Zhang, Z., Liu, F. & Chen, J. Molecular structure of the ATP-bound, phosphorylated human  
417 CFTR. *Proc. Natl. Acad. Sci. U. S. A.* (2018) doi:10.1073/pnas.1815287115.

418 37. Liu, F. *et al.* Structural identification of a hotspot on CFTR for potentiation. *Science* **364**, 1184–  
419 1188 (2019).

420 38. Fay, J. F. *et al.* Cryo-EM Visualization of an Active High Open Probability CFTR Anion  
421 Channel. *Biochemistry* **57**, 6234–6246 (2018).

422 39. Carveth, K., Buck, T., Anthony, V. & Skach, W. R. Cooperativity and flexibility of cystic  
423 fibrosis transmembrane conductance regulator transmembrane segments participate in membrane  
424 localization of a charged residue. *J. Biol. Chem.* **277**, 39507–39514 (2002).

425 40. Song, D., Jiao, H. & Liu, Z. Phospholipid translocation captured in a bifunctional membrane  
426 protein MprF. *Nat. Commun.* **12**, 2927 (2021).

427 41. Kishi, K. E. *et al.* Structural basis for channel conduction in the pump-like channelrhodopsin  
428 ChRmine. 2021.08.15.456392 <https://www.biorxiv.org/content/10.1101/2021.08.15.456392v1> (2021)  
429 doi:10.1101/2021.08.15.456392.

430 42. Ivetac, A. & Sansom, M. S. P. Molecular dynamics simulations and membrane protein structure  
431 quality. *Eur. Biophys. J. EBJ* **37**, 403–409 (2008).

432 43. McCoy, A. J., Sammito, M. D. & Read, R. J. Possible Implications of AlphaFold2 for  
433 Crystallographic Phasing by Molecular Replacement. *bioRxiv* 2021.05.18.444614 (2021)  
434 doi:10.1101/2021.05.18.444614.

435 44. Tsaban, T. *et al.* Harnessing protein folding neural networks for peptide-protein docking.  
436 *bioRxiv* 2021.08.01.454656 (2021) doi:10.1101/2021.08.01.454656.

437 45. Nguyen, P. H. *et al.* Amyloid Oligomers: A Joint Experimental/Computational Perspective on  
438 Alzheimer’s Disease, Parkinson’s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis. *Chem.*  
439 *Rev.* **121**, 2545–2647 (2021).

440 46. Padanyi, R. *et al.* Nanomechanics combined with HDX reveal allosteric drug binding sites of  
441 CFTR NBD1. 2021.08.20.457065 <https://www.biorxiv.org/content/10.1101/2021.08.20.457065v1>  
442 (2021) doi:10.1101/2021.08.20.457065.

443 47. Eddy, S. R. Accelerated Profile HMM Searches. *PLOS Comput. Biol.* **7**, e1002195 (2011).

444 48. Cock, P. J. A. *et al.* Biopython: freely available Python tools for computational molecular  
445 biology and bioinformatics. *Bioinformatics* **25**, 1422–1423 (2009).

446 49. Michaud-Agrawal, N., Denning, E. J., Woolf, T. B. & Beckstein, O. MDAnalysis: a toolkit for  
447 the analysis of molecular dynamics simulations. *J. Comput. Chem.* **32**, 2319–2327 (2011).

448 50. Harris, C. R. *et al.* Array programming with NumPy. *Nature* **585**, 357–362 (2020).

449 51. Hunter, J. D. Matplotlib: A 2D Graphics Environment. *Comput. Sci. Eng.* **9**, 90–95 (2007).

450 52. Zhang, Y. & Skolnick, J. TM-align: a protein structure alignment algorithm based on the TM-  
451 score. *Nucleic Acids Res.* **33**, 2302–2309 (2005).

452 53. Fiser, A. & Sali, A. Modeller: generation and refinement of homology-based protein structure  
453 models. *Methods Enzymol.* **374**, 461–491 (2003).

454 54. Larkin, M. A. *et al.* Clustal W and Clustal X version 2.0. *Bioinforma. Oxf. Engl.* **23**, 2947–2948  
455 (2007).

456 55. Huang, J. *et al.* CHARMM36m: an improved force field for folded and intrinsically disordered  
457 proteins. *Nat. Methods* **14**, 71–73 (2017).

458 56. Abraham, M. J. *et al.* GROMACS: High performance molecular simulations through multi-  
459 level parallelism from laptops to supercomputers. *SoftwareX* **1–2**, 19–25 (2015).

460 57. Jo, S., Kim, T., Iyer, V. G. & Im, W. CHARMM-GUI: a web-based graphical user interface for  
461 CHARMM. *J Comput Chem* **29**, 1859–1865 (2008).

462 58. Wu, E. L. *et al.* CHARMM-GUI Membrane Builder toward realistic biological membrane  
463 simulations. *J Comput Chem* **35**, 1997–2004 (2014).

464 59. Lomize, M. A., Lomize, A. L., Pogozheva, I. D. & Mosberg, H. I. OPM: orientations of proteins  
465 in membranes database. *Bioinforma. Oxf. Engl.* **22**, 623–625 (2006).

466 60. Darden, T., York, D. & Pedersen, L. Particle mesh Ewald: An N·log(N) method for Ewald sums  
467 in large systems. *J. Chem. Phys.* **98**, 10089–10092 (1993).

468 61. Hess, B., Bekker, H., Berendsen, H. J. C. & Fraaije, J. G. E. M. LINCS: A linear constraint  
469 solver for molecular simulations. *J. Comput. Chem.* **18**, 1463–1472 (1997).

470 62. Petrek, M. *et al.* CAVER: a new tool to explore routes from protein clefts, pockets and cavities.  
471 *BMC Bioinformatics* 7, 316 (2006).  
472

473 **Acknowledgements.** We thank H. Tordai, R. Padányi (Semmelweis University, Hungary) and G.  
474 Gyimesi (University of Bern, Switzerland) for their helpful suggestions. We acknowledge the  
475 computational resources made available B. Babics (Boblem IT Co.), Governmental Information-  
476 Technology Development Agency (<https://hpc.kifu.hu>), the Grubmüller laboratory at Max Planck  
477 Institute (<https://www.mpibpc.mpg.de/grubmueller>), and Wigner GPU Laboratory  
478 (<http://gpu.wigner.mta.hu>) and we thank the help of their members. This work was supported by funds  
479 to T. Hegedűs from the Cystic Fibrosis Foundation (CFF): HEGEDU20I0 and from NRDIO/NKFIH:  
480 K127961; to G. Lukacs from CCF LUKACS20G0, CIHR, CFI and Canada Research Chair Program to  
481 G. Lukacs; to M. Geisler from the Swiss National Funds (310030\_197563).

482


483 **Author contributions.** TH, MG, and GL conceived ideas and wrote the manuscript. TH and BF  
484 performed calculations and their analysis.

485

486 **Competing interests.** None.

487


488 **Materials & Correspondence** should be addressed to TH.



489


490 **Fig. 1: Quantitative analysis of human AF TM structures.** (A) Mean pLDDT scores were calculated  
491 for human transmembrane (TMEM), soluble (SOLU), TM regions of TM proteins, and non-TM regions  
492 of the same proteins. The fraction of structures in reliability ranges, used in the human proteome  
493 AlphaFold2 paper<sup>5</sup>, are shown. (B) The hydrophobic thickness was calculated for human TM proteins as  
494 the distance between the center of geometry of C $\alpha$  atoms of side1 and side2 of transmembrane helices.  
495 TM helices of AF2-structures were selected based on CCTOP predictions. The hydrophobic thickness of  
496 experimental structures was collected from PDBTM. (C) The hydrophobic thickness of each protein and  
497 the corresponding pLDDT scores were plotted. (D) The hydrophobic thickness of each protein and the  
498 corresponding CCTOP reliability scores are shown.

499




500

501 **Fig. 2: All AF2-predicted ABC structures exhibit valid ABC TM folds.** (A) The best TM-score for  
502 every ABC TM structure from the 21 organisms calculated against every 8 ABC reference folds were  
503 selected and plotted. (B) The AF-Q2G2E2 fold with a TM-score lower than 0.5. This YitT fold is  
504 annotated incorrectly in PFAM and is not an ABC fold. (C) The Aquaporin/GlpF fold, which is somewhat  
505 similar to YitT fold and is represented by PDBID: 1FX8, possesses six TM helices and two reentrant  
506 helices forming a full TM helix-like structure.



508 **Fig. 3: AF2 seems to handle ABC structure associated issues correctly.** (A) ABCG2 and ABCG8  
509 NBD  $\beta$ 1 strand sequence alignments generated by structural alignment of 6HCO (ABCG2) and 5DO7  
510 (ABCG5/ABCG8), by ClustalW with manual adjustment of ABCG2 and ABCG8 sequences based on  
511 ABCG2 structures, and by structural alignment of ABCG2 and AF2-predicted ABCG8 NBDs. Structure:  
512 AF2 ABCG8 NBD, blue:  $\beta$ 1 strand, red: the segment corresponding to the  $\beta$ 1 strand in the registry shifted  
513 5DO7 NBD, cyan: gating loop or regulatory insertion. (B) Structural alignment of 5DO7 (gray) and AF2-  
514 predicted (blue) ABCG5/ABCG8 TM domains (top view). Non-conserved loops with low-quality  
515 predictions are red. (C) Aligned homology (orange: TMD1, red: TMD2) and AF2 (blue: TMD1, cyan:  
516 TMD2) models of AtABCG36. Blue and orange spheres label F589 and F592 in TM2 facing the substrate  
517 binding pocket. (D) The magnified view of AtABCG36 TM1 and TM2 indicates that the alignments are  
518 not shifted but that spatial localization and side chain packing differ. (E) TM2 in the homology model  
519 unwinds in MD simulations. (F) zfCFTR TM8 is kinked in PDBID:5W81 (red) along with other  
520 structures and it is straight in both MRP1-based model (orange) and AF2-predicted structure (blue). The  
521 helices are extracted for visualization from a full TM domain alignment. (G) Surface representation of  
522 zfCFTR (PDBID:5W81). Red: TM8, green: TMD1, cyan: TMD2, pale green: NBD1, pale cyan: NBD2,  
523 black spheres: CAVER spheres indicating channel opening towards the extracellular space and the  
524 extracellular boundary of the lipid bilayer. (H) Surface representation of zfCFTR with MRP1-modelled,  
525 straight TM8. No lateral opening to the extracellular membrane leaflet can be observed.

526



524

525 **Fig. 4: Predicting new TM folds.** (A) The novel TM fold of MprF (PDBID: 7DUW). Blue to red: N- to C-termini. (B) An AF2-predicted fold that significantly differs from the experimentally determined fold (e.g. N-terminus starts on the opposite side of the membrane). (C) pLDDT and TM-score values, calculated for every structural model from six runs, were plotted. Numbers (1-5) indicate the corresponding AF2 models. Red points were the top ranked hits from a given run. (D) Structural alignment of the experimental structure (rainbow colors) and the prediction with the best pLDDT score (gray).

526